Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Another radiation restenosis treatment tested :

This article was originally published in Clinica

Executive Summary

Theragenics, a US company that makes the Theraseed prostate brachytherapy device, is to test its palladium-103 technology on animal models of coronary restenosis. The Buford, Georgia-based company has signed an agreement with the Atlanta Cardiovascular Research Institute to conduct a two-phase animal study, due to begin next month. The first phase will aim to determine whether a catheter-based Pd-103 source can inhibit restenosis, while the second will test stent-based Pd-103 devices. Theragenics is the latest in a long line of companies trying to exploit the anti-restenotic properties of various types of radiation sources.

You may also be interested in...

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine

As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts